Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Forgot Sakai

<< Previous

Bullboard Posts

Next >>

Comment by PWIB123on Nov 12, 2022 3:56pm

139 Views

Post# 35093990

RE:RE:RE:RE:RE:RE:Forgot Sakai

I guess you could look at that several ways, but obviously invstors wanted more and weren't given those details. The success of the lawsuit's defense seems to have emboldened THTX to stick to their history of providing less communication. I would've agreed with the courts on this one. I think they made the right call, but that doesn't mean THTX is doing the right thing in how they communicate with investors.

Lee430 wrote: Perhaps this is the reason for their ultra conservative PR stance.

https://www.theglobeandmail.com/report-on-business/industry-news/the-law-page/top-court-tosses-suit-against-theratechnologies/article24004231/

Joemare wrote: I think it's fine to voice your opinion. Not sure how busy she is. Very quiet on linked-in and twitter.....